BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7567779)

  • 1. Characterization of a P2Y purinoceptor in the brain.
    Simon J; Webb TE; Barnard EA
    Pharmacol Toxicol; 1995 May; 76(5):302-7. PubMed ID: 7567779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P2Y purinoceptor in rat brain microvascular endothelial cells couple to inhibition of adenylate cyclase.
    Webb TE; Feolde E; Vigne P; Neary JT; Runberg A; Frelin C; Barnard EA
    Br J Pharmacol; 1996 Dec; 119(7):1385-92. PubMed ID: 8968547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of [35S]-ATP alpha S and [3H]-alpha, beta-MeATP binding sites in rat brain cortical synaptosomes: regulation of ligand binding by divalent cations.
    Schäfer R; Reiser G
    Br J Pharmacol; 1997 Jul; 121(5):913-22. PubMed ID: 9222547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of [35S]adenosine 5'-O-(2-thiodiphosphate) to endothelial cells in culture.
    Wilkinson GF; Boarder MR
    Biochem Pharmacol; 1995 May; 49(10):1411-8. PubMed ID: 7763284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of a recombinant P2Y purinoceptor.
    Simon J; Webb TE; King BF; Burnstock G; Barnard EA
    Eur J Pharmacol; 1995 Nov; 291(3):281-9. PubMed ID: 8719412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High affinity P2x-purinoceptor binding sites for [35S]-adenosine 5'-O-[3-thiotriphosphate] in rat vas deferens membranes.
    Michel AD; Humphrey PP
    Br J Pharmacol; 1996 Jan; 117(1):63-70. PubMed ID: 8825344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and characterisation of [3H]alpha,beta-methylene ATP binding sites in the rat.
    Michel AD; Humphrey PP
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Dec; 348(6):608-17. PubMed ID: 8133903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the binding characteristics of recombinant P2X1 and P2X2 purinoceptors.
    Michel AD; Lundström K; Buell GN; Surprenant A; Valera S; Humphrey PP
    Br J Pharmacol; 1996 Aug; 118(7):1806-12. PubMed ID: 8842447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 6H1 as a P2Y purinoceptor: P2Y5.
    Webb TE; Kaplan MG; Barnard EA
    Biochem Biophys Res Commun; 1996 Feb; 219(1):105-10. PubMed ID: 8619790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoradiographic labelling of P2 purinoceptors in the guinea-pig cochlea.
    Mockett BG; Bo X; Housley GD; Thorne PR; Burnstock G
    Hear Res; 1995 Apr; 84(1-2):177-93. PubMed ID: 7642450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for P2-purinoceptor-mediated inhibition of noradrenaline release in rat brain cortex.
    von Kügelgen I; Späth L; Starke K
    Br J Pharmacol; 1994 Nov; 113(3):815-22. PubMed ID: 7858872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of [35S]dATPalphaS interaction with P2Y1 purinoceptor in rat brain membranes.
    Oras A; Järv J
    Neurosci Lett; 2004 Jan; 355(1-2):9-12. PubMed ID: 14729222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The binding characteristics of a human bladder recombinant P2X purinoceptor, labelled with [3H]-alpha beta meATP, [35S]-ATP gamma S or [33P]-ATP.
    Michel AD; Lundström K; Buell GN; Surprenant A; Valera S; Humphrey PP
    Br J Pharmacol; 1996 Mar; 117(6):1254-60. PubMed ID: 8882623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ap4A and ADP-beta-S binding to P2 purinoceptors present on rat brain synaptic terminals.
    Pintor J; Díaz-Rey MA; Miras-Portugal MT
    Br J Pharmacol; 1993 Apr; 108(4):1094-9. PubMed ID: 8485620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of [35S]dATP alpha S binding sites in the adult rat neuraxis.
    Simon J; Webb TE; Barnard EA
    Neuropharmacology; 1997 Sep; 36(9):1243-51. PubMed ID: 9364479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation by 2,2'-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor.
    King BF; Dacquet C; Ziganshin AU; Weetman DF; Burnstock G; Vanhoutte PM; Spedding M
    Br J Pharmacol; 1996 Mar; 117(6):1111-8. PubMed ID: 8882604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor.
    Schachter JB; Harden TK
    Br J Pharmacol; 1997 May; 121(2):338-44. PubMed ID: 9154346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of [35S]dATP alpha S interaction with P2y(1) nucleotide receptor.
    Oras A; Kilk K; Kunapuli S; Barnard EA; Järv J
    Neurochem Int; 2002 Apr; 40(5):381-6. PubMed ID: 11821144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel P2-purinoceptor expressed by a subpopulation of astrocytes from the dorsal spinal cord of the rat.
    Ho C; Hicks J; Salter MW
    Br J Pharmacol; 1995 Dec; 116(7):2909-18. PubMed ID: 8680724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of vascular P2 purinoceptors in the rat isolated perfused kidney.
    Eltze M; Ullrich B
    Eur J Pharmacol; 1996 Jun; 306(1-3):139-52. PubMed ID: 8813626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.